Paricalcitol

OPKO Health to Present New Clinical Data on Rayaldee (ER Calcifediol) at Kidney Week 2023

Retrieved on: 
Wednesday, October 25, 2023

MIAMI, Oct. 25, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) will present late-breaking clinical data on RAYALDEE® extended-release calcifediol (ERC) at the American Society of Nephrology (ASN) Kidney Week in Philadelphia on Thursday, November 2, 2023.

Key Points: 
  • MIAMI, Oct. 25, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) will present late-breaking clinical data on RAYALDEE® extended-release calcifediol (ERC) at the American Society of Nephrology (ASN) Kidney Week in Philadelphia on Thursday, November 2, 2023.
  • OPKO Health will present two other posters at ASN Kidney Week summarizing additional new clinical data on RAYALDEE.
  • The data demonstrate that effective control of SHPT has been achieved with RAYALDEE treatment in both randomized clinical trials and in a real-world clinical experience trial.
  • Data from these trials support early initiation of SHPT treatment with RAYALDEE in order to delay disease progression.

FDA Approves First Extended-Release, Injectable Drug Regimen for Adults Living with HIV

Retrieved on: 
Thursday, January 21, 2021

"Currently, the standard of care for patients with HIV includes patients taking daily pills to adequately manage their condition.

Key Points: 
  • "Currently, the standard of care for patients with HIV includes patients taking daily pills to adequately manage their condition.
  • "Having this treatment available for some patients provides an alternative for managing this chronic condition."
  • The most common adverse reactions with Cabenuva were injection site reactions, fever (pyrexia), fatigue, headache, musculoskeletal pain, nausea, sleep disorders, dizziness and rash.
  • Cabenuva and Vocabria were granted Fast Track and Priority Review designation by the FDA.

Viking Therapeutics Presents Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol in Oral Late-Breaker Presentation at The Liver Meeting® 2018

Retrieved on: 
Monday, November 12, 2018

Overall adverse events were evenly distributed across all cohorts, with a slightly greater incidence among patients receiving placebo compared with VK2809-treated patients.

Key Points: 
  • Overall adverse events were evenly distributed across all cohorts, with a slightly greater incidence among patients receiving placebo compared with VK2809-treated patients.
  • By comparison, patients with elevated baseline ALT levels treated with placebo (n=5) experienced an increase from baseline of 11.6 U/L at Week 16.
  • Mean aspartate aminotransferase (AST) levels among VK2809-treated patients were also reduced relative to placebo at Weeks 12 and 16.
  • In addition, no changes to the thyroid hormone axis were observed among VK2809-treated patients compared with placebo-treated patients.